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the ED and subsequently admitted as inpatients were considered
as one encounter. Encounters with hypoglycemia were catego-
rized into 3 mutually exclusive groups: 1) encounters due to
hypoglycemia required a primary inpatient diagnosis or any ED
diagnosis of hypoglycemia (ICD-9-CM code 251.0, 251.1, or
251.2); 2) encounters in which patients presented with hypogly-
cemia (ie, ﬁrst lab blood glucose [BG] during the ﬁrst 24 hours in
the hospital < 70 mg/dL); and 3) encounters in which patients
developed hypoglycemia only after the ﬁrst 24 hours in the
hospital. Outcomes were total charges, length of stay, discharge
to a skilled nursing facility (SNF), and inpatient mortality.
Encounter types 2 and 3 were each compared with encounters
without hypoglycemia (ie, all BG values 70 mg/dL). Compari-
sons were adjusted for potential confounders (e.g., reasons for
hospitalization, comorbidities, propensity score for hypoglyce-
mia) using multivariate regression models. Hypoglycemia was
rarely used as a primary diagnosis. Of 519,317 encounters
(n = 215,922 diabetic patients), 732 (0.14%) had hypoglycemia
as the reason for the encounter, and most (91%) were ED only
without admission. However, in 8971 encounters (1.73%),
patients presented with hypoglycemia. In an additional 19,487
encounters (3.75%), patients developed hypoglycemia. All out-
comes for patients who developed hypoglycemia were signiﬁ-
cantly different than those for patients without hypoglycemia.
However, only charges and odds of discharge to a SNF were
signiﬁcantly associated with presentation with hypoglycemia.
The effect of hypoglycemia on outcomes depends on when
hypoglycemia is deﬁned and is more pronounced in patients who
developed hypoglycemia than in patients who presented with
hypoglycemia.
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OBJECTIVE: This study estimates the prevalence of type 2 dia-
betes (T2DM) in youth treated in a primary care setting. Pub-
lished prevalence estimates range from 0.2 to 1.5 per 1000,
varying by estimation population. This study also quantiﬁes the
association between T2DM and obesity and seeks to conﬁrm
clinical links that have been established between T2DM among
youth and obesity. METHODS: A cross-sectional analysis was
conducted in the General Electric Electronic Medical Record
(EMR) database in 2002 and 2006. The prevalence population
included youth aged 5 to 19 with continuous database activity
during the year. T2DM included two T2DM ICD-9 codes, one
T2DM ICD-9 code and a prescription for insulin, a prescrip-
tion for an oral antidiabetic agent, or two fasting blood glucose
levels 126 mg/dl during or prior to the estimation year,
without type 1 diabetes or polycystic ovary syndrome. Findings
were stratiﬁed by baseline BMI. The odds of developing T2DM
by BMI category were estimated by logistic regression.
RESULTS: The 2002 and 2006 prevalence populations
included 89,087 and 107,857 youth respectively. The preva-
lence of T2DM per 1000 was 2.20 in 2002 and 4.45 in 2006.
Of those with a baseline BMI reading, 8.0% and 9.4% were
obese (BMI > 30 kg/m2) in 2002 and 2006 respectively. T2DM
prevalence in the obese was 6.8 and 22.7 per 1000 in 2002 and
2006 respectively; age, gender and race adjusted odds of the
obese developing T2DM relative to the normal weight popula-
tion were 6.56 and 11.49 in 2002 and 2006 respectively
(P < 0.001 for both). CONCLUSION: Obesity substantially
increases T2DM risks. The prevalence of T2DM in a popula-
tion of youth routinely treated in a primary care setting is
higher than other recent estimates and increased dramatically in
a four year time frame. Additional research is warranted
to identify treatment trends and outcomes in youth with
T2DM.
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OBJECTIVE: The rate of heart disease is 1.5-fold greater among
Aboriginals compared to the general Canadian population. Risk
factors such as smoking, hypertension, dyslipidemia, obesity and
diabetes are also more prevalent. For example, type 2 diabetes is
3.6–5.3 times more prevalent among Aboriginals. Obesity is
relatively common in diabetes, contributing to poor diabetes
control and the development of its associated complications. It is
of interest to compare the prevalence of obesity among Aborigi-
nals with diabetes to all Canadians with diabetes. METHODS: A
MEDLINE search was conducted (1966–2007) using the follow-
ing MeSH terms: Indians—North American, Canada, diabetes
mellitus, obesity and body mass index (BMI). Population-based
studies reporting the proportion of Aboriginals with diabetes
that were overweight (e.g.25 kg/m2 for women,27 kg/m2 for
men) or obese (30 kg/m2) were retrieved. Prevalence estimates
of elevated BMIs for Canadians with diabetes were obtained
from the LCDC National Population Survey (1996–1997) and
the Ontario Diabetes Database (1996–1997; Ontario Health
Survey). RESULTS: Twenty-three studies were retrieved. Seven-
teen studies were excluded because either the patient populations
or deﬁnitions of obesity/overweight differed between studies.
Ranges of 76.2–86.5% of Aboriginals with diabetes were either
overweight or obese compared to 59.4% of all Canadians with
diabetes. Furthermore, 44.1–69.6% of Aboriginals with diabetes
were obese compared to 28.6% of all Ontarians with diabetes.
CONCLUSION: When compared with the general Canadian
population with diabetes, elevated BMI is more commonly
observed among Aboriginals with diabetes. These ﬁndings
suggest that obesity, as a risk factor for poor diabetes control and
heart disease, is not optimally managed within the Aboriginal
diabetes population and may pose a great burden to the Aborigi-
nal community. The precise impact of obesity and diabetes on the
health of Aboriginals warrants further research.
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OBJECTIVE: To estimate prevalence of hospitalizations in dia-
betic patients, to determine factors which inﬂuence hospitaliza-
tions attributable to diabetes, and to calculate length of stay
(LOS) using health insurance claims data. METHODS: This
retrospective cohort study used health insurance claims data
collected from three Catholic University Medical Centers in
South Korea. Type 2 diabetes patients were identiﬁed if patients
received treatment for diabetes (ICD-10 code of E11x) at least
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once annually during the study period of 2000–2005, were >=30
years old, and did not have a diagnosis of pregnancy or cancer.
Hospitalization attributable to diabetes was deﬁned as admis-
sions due to diabetes, diabetic complications, or cardiovascular
diseases. Cox-proportional hazard model was developed to
determine signiﬁcant factors for hospitalizations after adjusting
for the study variables. Two-part model (First part: logistic
regression and second part: generalized linear model with log
link function) was utilized to estimate mean length of stay.
RESULTS: A total of 7952 patients with type 2 diabetes were
identiﬁed with mean age of 57.4. Approximately 5.4% of them
were hospitalized due to diabetes. Type 2 diabetes patients were
more likely to be admitted if they were older than 65 years
(relative risk (RR) = 1.36; 95% conﬁdence interval
(95%CI) = 1.09–1.71), took both insulin and oral antidiabetic
medications (RR = 4.31; 95% CI = 3.30–5.63) compared to
patients without diabetic treatment, or had frequent physician
ofﬁce visits (RR = 2.06; 95% CI = 1.53–2.76). Overall, patients
stayed at the hospital on average of 2.23  0.08 days. CON-
CLUSION: Type 2 diabetes patients who took both insulin and
oral antidiabetic medications due to poor glucose control were
more likely to be admitted to hospital. It is recommended that
aggressive early intervention for controlling blood glucose and
improving compliance with diabetes treatment may prevent hos-
pitalizations related with diabetes.
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OBJECTIVE: Physician pay-for-performance are gaining
momentum as an approach to improve health care quality in the
United States. The objective of this study was to show the ben-
eﬁcial effects of physician incentive programs for the treatment of
diabetic patients as well as the potential for cost saving.
METHODS: Administrative claims data from a large regional
health plan were used through the 2004–2005 time-frame. Dia-
betic patients age 18–75 with private health insurance coverage
were included in the analysis. Multivariate Poisson regression
was used to model the likelihood of diabetes-related hospitaliza-
tions between patients who were being treated by a physician
participating in the incentive program and those that were not.
Likewise, cost savings associated with diabetic patients treated
by physicians participating in the incentive program was also
computed. RESULTS: Over a two year period, patients in the
P4P program showed a lower combined predicted number of
hospitalizations (0.31) than that of patients not in a P4P program
(0.39). In addition, cost beneﬁt analysis using decision tree mod-
eling showed the costs of the P4P program was entirely covered
by the reduction in cost resulting from decreased hospitalization
rates. With the incentive program, the health plan saved approxi-
mately $24 per adult diabetic and a total cost savings of
$675,000. Sensitivity analysis shows that the higher quality of
care resulting from the incentive based programs directly beneﬁts
outcomes of diabetes patients with an added beneﬁt of reducing
program cost. CONCLUSION: The cost savings associated with
physician pay-for-performance programs depend highly on the
effectiveness of the program to improve delivery of quality care.
Physician incentive programs have the potential to improve
patient outcomes as well as lead to economic beneﬁts for payers.
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OBJECTIVE: To develop a model to predict the probability of
diabetes patients having inpatient hospitalization in the follow-
ing year. METHODS: A retrospective cohort study was con-
ducted based on a population of 322 type II diabetes patients age
>=19 and enrolled in a Medicaid managed care plan from the
year 2003 to 2005. Models were developed by using medical/
pharmacy utilization data to predict the probability of having the
following events in the next year: (1) whether the patient had any
inpatient hospitalization, (2) whether the patient had any micro/
macro vascular inpatient hospitalization, (3) whether the patient
had any metabolic related inpatient hospitalization and (4)
whether the patient had any infectious inpatient hospitalization.
Main predictors of interests are diabetes compliance and the use
of statin. Covariates include diabetes treatment pattern, age, sex,
co-morbidities among other variables. Logistic model is used to
conduct the analysis. RESULTS: The study population was 74%
female with an average age of 49.2 (S.D = 8.4). Non-adherence
of diabetes drug (odds ratio = 1.57, 95% CI: 1.09–2.24), use of
statin (odds ratio = 0.58, 95% CI: 0.39–0.85), and previous
inpatient history (odds ratio = 3.50, 95% CI: 2.42–5.07) were
signiﬁcant in predicting any inpatient hospitalization. Non-
adherence of diabetes drugs was not a signiﬁcant predictor for
micro/macro vascular events (odds ratio = 0.74, 95% CI: 0.33–
1.67), but it was associated with signiﬁcantly increased prob-
abilities of having metabolic events (odds ratio = 1.58, 95% CI:
1.03–2.43) and infectious events (odds ratio = 2.70, 95% CI:
1.10–6.66). The use of statin was signiﬁcant only for predicting
metabolic events (odds ratio = 0.49, 95% CI: 0.32–0.77). It was
not signiﬁcant for predicting vascular events (odds ratio = 0.98,
95% CI: 0.45–2.15) and infectious events (odds ratio = 1.40,
95% CI: 0.49–3.72). CONCLUSION: The modeling results
show that improving compliance of diabetes drug and encourag-
ing the use of statin could be associated with reducing inpatient
hospitalizations in a short period of time.
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OBJECTIVE: To assess the budgetary impact of adding the ﬁxed-
dose pioglitazone plus glimepiride to a managed care formulary
plan over a three-year period (2006–2008). METHODS: This
model is an Excel-based spreadsheet which assumes a hypotheti-
cal scenario wherein a plan comprising one million covered lives
assesses the ﬁnancial impact of pioglitazone plus glimepiride to
formulary. The prevalence of type 2 diabetes is assumed to be
4.64% or approximately 46,400 members. Existing oral anti-
diabetic (OAD) agents on the formulary include TZDs (pioglita-
zone, rosiglitazone, TZD combinations with metformin, &
rosiglitazone plus glimepiride), sulfonylureas (glipizide, gly-
buride, glimeperide), metformin, & a DPP4 inhibitor (sitaglip-
tin). Costs for these agents were based on WAC (2006). Market
shares were based on internal market research and IMS data.
Metrics of budgetary impact are reported in terms of annual
treatment costs & per member per month (PMPM) costs. These
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